Proceeding contribution from Paul Flynn (Labour) in the House of Commons on Thursday, 8 December 2005. It occurred during Estimates day on Department of Health.
Department of Health
Is the hon. Gentleman aware that Eliot Spitzer in New York took GlaxoSmithKlein to court and the company was fined? That revealed a truly shocking picture of falsified research: negative results were ignored; results showing that new drugs were not as effective as placebos had been buried and not published; and the results of trials during which people had died had been suppressed. That is a dreadful record and although I tried to congratulate the drug companies on having changed their act, the past is one of deception, errors and manipulation on a scale that most of us could not imagine.
Secondary information
- Type
- Proceeding contribution
- Reference
- 440 c1057
- Session
- 2005-06
- Chamber / Committee
- House of Commons chamber
- Subjects
- Advertising Licensing Expenditure Drugs Government departments Industry Prescription drugs Department of Health Medicines and Healthcare products Regulatory Agency Research Regulation Safety National Institute for Health and Care Excellence Registration Clinical trials
- Link
- View this Proceeding contribution on www.publications.parliament.uk
Librarians' tools
- Timestamp
- 2025-11-24 15:50:32 +0000
- URI
- http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285147
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285147
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/pimsdata/hansard/CONTRIBUTION_285147